{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:32:51Z","timestamp":1775835171591,"version":"3.50.1"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"am","delay-in-days":357,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimie"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.biochi.2020.08.018","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T02:37:10Z","timestamp":1599100630000},"page":"266-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?"],"prefix":"10.1016","volume":"179","author":[{"given":"Pierre-Jean","family":"Ferron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gicquel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"M\u00e9garbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Fromenty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biochi.2020.08.018_bib1","first-page":"S0168","article-title":"COVID-19 and liver","author":"Jothimani","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m1996","article-title":"Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series","author":"Argenziano","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.biochi.2020.08.018_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/oby.22923","article-title":"Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York city","author":"Hajifathalian","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.biochi.2020.08.018_bib4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/oby.22831","article-title":"High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation","volume":"28","author":"Simonnet","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.biochi.2020.08.018_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41574-020-0353-9","article-title":"Endocrine and metabolic link to coronavirus infection","volume":"16","author":"Bornstein","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biochi.2020.08.018_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.etap.2020.103411","article-title":"Two important controversial risk factors in SARS-CoV-2 infection: obesity and smoking","volume":"78","author":"Engin","year":"2020","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108142","article-title":"COVID-19 and diabetes: knowledge in progress","volume":"162","author":"Hussain","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.biochi.2020.08.018_bib8","doi-asserted-by":"crossref","first-page":"E736","DOI":"10.1152\/ajpendo.00124.2020","article-title":"COVID-19 pandemic, coronaviruses, and diabetes mellitus","volume":"318","author":"Muniyappa","year":"2020","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biochi.2020.08.018_bib9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/oby.22843","article-title":"Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019?","volume":"28","author":"Ryan","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.biochi.2020.08.018_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108464","article-title":"Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19","volume":"216","author":"Omarjee","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biochi.2020.08.018_bib11","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jhep.2020.03.044","article-title":"Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study","volume":"73","author":"Ji","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gutjnl-2020-321611","article-title":"Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.biochi.2020.08.018_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31480","article-title":"Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis","author":"Bertolini","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.biochi.2020.08.018_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/2050640620924157","article-title":"Liver injury in COVID-19: the current evidence","volume":"8","author":"Alqahtani","year":"2020","journal-title":"United European Gastroenterol. J."},{"key":"10.1016\/j.biochi.2020.08.018_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2020.00046","article-title":"Characteristics and mechanism of liver injury in 2019 coronavirus disease","volume":"8","author":"Li","year":"2020","journal-title":"J.\u00a0Clin. Transl. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2020.05.025","article-title":"SARS-CoV-2 related liver impairment \u2013 perception may not be the reality","author":"Philips","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2020.04.002","article-title":"Clinical features of COVID-19-related liver functional abnormality","volume":"18","author":"Fan","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib18","article-title":"Liver injury in COVID-19: management and challenges","volume":"428\u2013430","author":"Zhang","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib19","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00204-020-02734-1","article-title":"COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?","volume":"94","author":"Boeckmans","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","article-title":"Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity","volume":"67","author":"Fromenty","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/dmd.111.041400","article-title":"CPY3A4-Mediated lopinavir bioactivation and its inhibition by ritonavir","volume":"40","author":"Li","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.biochi.2020.08.018_bib22","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease","volume":"40","author":"Barlow","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biochi.2020.08.018_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biochi.2020.08.018_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/jcph.1646","article-title":"Hydroxychloroquine and azithromycin to treat patients with COVID-19: both friends and foes?","volume":"60","author":"M\u00e9garbane","year":"2020","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib25","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"13","author":"Sanders","year":"2020","journal-title":"JAMA Apr"},{"key":"10.1016\/j.biochi.2020.08.018_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijid.2020.05.026","article-title":"Use of anakinra in severe COVID-19: a case report","volume":"96","author":"Filocamo","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biochi.2020.08.018_bib27","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.cgh.2020.04.025","article-title":"Gastroenterologists, hepatologists, COVID-19 and the use of acetaminophen","volume":"18","author":"Rodr\u00edguez-Morales","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/apt.15813","article-title":"Review article: COVID-19 and liver disease-what we know on 1st May 2020","volume":"52","author":"Garrido","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0399-8320(04)95062-2","article-title":"[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]","volume":"28","author":"Biour","year":"2004","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.biochi.2020.08.018_bib30","article-title":"Clinical and research information on drug-induced liver injury","author":"LiverTox","year":"2012","journal-title":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)"},{"key":"10.1016\/j.biochi.2020.08.018_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fphar.2019.01482","article-title":"Drug-induced liver injury: biomarkers, requirements, candidates, and validation","volume":"10","author":"Meunier","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biochi.2020.08.018_bib33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/apt.15153","article-title":"Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis","volume":"49","author":"Regev","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaa340","article-title":"Drug interactions: a review of the unseen danger of experimental COVID-19 therapies","author":"Hodge","year":"2020","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.biochi.2020.08.018_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.taap.2009.04.002","article-title":"Synergistic drug\u2013cytokine induction of hepatocellular death as an in\u00a0vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity","volume":"237","author":"Cosgrove","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.tiv.2019.03.015","article-title":"Pro-inflammatory cytokines enhance dilatation of bile canaliculi caused by cholestatic antibiotics","volume":"58","author":"Sharanek","year":"2019","journal-title":"Toxicol. In\u00a0Vitro"},{"key":"10.1016\/j.biochi.2020.08.018_bib37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1872-034X.2007.00072.x","article-title":"A\u00a0prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease","volume":"37","author":"Tarantino","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.biochi.2020.08.018_bib38","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jhep.2012.12.018","article-title":"Drug-induced liver injury in obesity","volume":"58","author":"Fromenty","year":"2013","journal-title":"J.\u00a0Hepatol."},{"issue":"Suppl 1","key":"10.1016\/j.biochi.2020.08.018_bib39","first-page":"212","article-title":"Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity","volume":"3","author":"Massart","year":"2017","journal-title":"J.\u00a0Clin. Transl. Res."},{"key":"10.1016\/j.biochi.2020.08.018_bib40","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/apt.14952","article-title":"Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view","volume":"48","author":"Bessone","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib41","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1016\/j.cgh.2018.12.013","article-title":"Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may Be at higher risk for drug-induced liver injury","volume":"17","author":"Lammert","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib42","first-page":"8764093","article-title":"Metabolic comorbidities and risk of development and severity of drug-induced liver injury","volume":"2019","author":"Li","year":"2019","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.biochi.2020.08.018_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/bs.apha.2019.01.003","article-title":"Drug-induced liver injury in obesity and nonalcoholic fatty liver disease","volume":"85","author":"Allard","year":"2019","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib44","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1111\/liv.12514","article-title":"Acetaminophen-induced liver injury in obesity and nonalcoholic fatty liver disease","volume":"34","author":"Michaut","year":"2014","journal-title":"Liver Int."},{"key":"10.1016\/j.biochi.2020.08.018_bib45","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/cpt.1701","article-title":"Acetaminophen-induced liver damage in hepatic steatosis","volume":"107","author":"Garc\u00eda-Rom\u00e1n","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib46","doi-asserted-by":"crossref","first-page":"c6764","DOI":"10.1136\/bmj.c6764","article-title":"Acute liver failure after administration of paracetamol at the maximum recommended daily dose in adults","volume":"341","author":"Claridge","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.biochi.2020.08.018_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2020.110258","article-title":"Fatal acetaminophen poisoning with hepatic microvesicular steatosis in a child after repeated administration of therapeutic doses","volume":"310","author":"Bouvet","year":"2020","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.biochi.2020.08.018_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2019.11.012","article-title":"Chemotherapy-associated steatohepatitis","author":"Meunier","year":"2020","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkaa020","article-title":"Incidence, predictive factors, and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study","author":"Mori","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"key":"10.1016\/j.biochi.2020.08.018_bib50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.taap.2015.12.020","article-title":"A\u00a0cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: application to acetaminophen","volume":"292","author":"Michaut","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib51","doi-asserted-by":"crossref","first-page":"4396403","DOI":"10.1155\/2018\/4396403","article-title":"Possible involvement of mitochondrial dysfunction and oxidative stress in a cellular model of NAFLD progression induced by benzo[a]pyrene\/ethanol coexposure","author":"Bucher","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biochi.2020.08.018_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.117.246751","article-title":"Drug-induced alterations of mitochondrial DNA homeostasis in steatotic and nonsteatotic HepaRG cells","volume":"365","author":"Le Guillou","year":"2018","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib53","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1038\/s41598-018-24403-1","article-title":"Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in\u00a0vitro and in\u00a0vivo","volume":"8","author":"Bucher","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biochi.2020.08.018_bib54","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clinre.2011.04.015","article-title":"Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role","volume":"35","author":"Aubert","year":"2011","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.biochi.2020.08.018_bib55","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","article-title":"Impact of obesity on drug metabolism and elimination in adults and children","volume":"51","author":"Brill","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biochi.2020.08.018_bib56","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) \u2013 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biochi.2020.08.018_bib57","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/jpet.112.193813","article-title":"Differences in early acetaminophen hepatotoxicity between obese ob\/ob and db\/db mice","volume":"342","author":"Aubert","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib58","article-title":"Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity","author":"Allard","year":"2020","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib59","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s13181-015-0488-6","article-title":"A\u00a0review of the toxicologic implications of obesity","volume":"11","author":"Zuckerman","year":"2015","journal-title":"J.\u00a0Med. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib60","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.biochi.2020.08.018_bib61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biochi.2020.08.018_bib62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/03602532.2011.604086","article-title":"Central role of mitochondria in drug-induced liver injury","volume":"44","author":"Pessayre","year":"2012","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biochi.2020.08.018_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-3-642-00663-0_11","article-title":"Mitochondrial involvement in drug-induced liver injury","volume":"196","author":"Pessayre","year":"2010","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib64","first-page":"75","article-title":"Mitochondrial dysfunction as a mechanism of drug-induced hepatotoxicity: current understanding and future perspectives","volume":"4","author":"Ramachandran","year":"2018","journal-title":"J.\u00a0Clin. Transl. Res."},{"key":"10.1016\/j.biochi.2020.08.018_bib65","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.biochi.2020.08.018_bib66","article-title":"Cytochrome P450 2E1 should not be neglected for acetaminophen-induced liver injury in metabolic diseases with altered insulin levels or glucose homeostasis","volume":"19","author":"Massart","year":"2020","journal-title":"Clin. Res. Hepatol. Gastroenterol. Jun"},{"key":"10.1016\/j.biochi.2020.08.018_bib67","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/jpet.105.084608","article-title":"Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes","volume":"315","author":"Abdelmegeed","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biochi.2020.08.018_bib68","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial adaptation in nonalcoholic fatty liver disease: novel mechanisms and treatment strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.biochi.2020.08.018_bib69","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127737","article-title":"Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver","volume":"4","author":"Fletcher","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.biochi.2020.08.018_bib70","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/mol.116.104687","article-title":"A\u00a0fibroblast growth factor 21\u2013pregnane X receptor pathway downregulates hepatic CYP3A4 in nonalcoholic fatty liver disease","volume":"90","author":"Woolsey","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cbi.2019.05.038","article-title":"CYP3A suppression during diet-induced nonalcoholic fatty liver disease is independent of PXR regulation","volume":"308","author":"Zeng","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biochi.2020.08.018_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2010.02301.x","article-title":"Drug-drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition: drug-drug interactions in the treatment of HIV infection","volume":"268","author":"Josephson","year":"2010","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.biochi.2020.08.018_bib74","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","article-title":"Plaquenil Lupus Systemic Study Group, Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus","volume":"67","author":"Jallouli","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.biochi.2020.08.018_bib75","first-page":"12815","article-title":"What do we know about remdesivir drug interactions?","author":"Yang","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.biochi.2020.08.018_bib76","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003088-200140110-00004","article-title":"Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions","volume":"40","author":"Pea","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.biochi.2020.08.018_bib77","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.livres.2019.06.001","article-title":"Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis","volume":"3","author":"Fromenty","year":"2019","journal-title":"Liver Research"},{"key":"10.1016\/j.biochi.2020.08.018_bib78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.biochi.2020.08.018_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110916","article-title":"Alteration of mitochondrial DNA homeostasis in drug-induced liver injury","volume":"135","author":"Fromenty","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib80","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jhep.2010.11.006","article-title":"Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver","volume":"54","author":"Begriche","year":"2011","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jhep.2003.50309","article-title":"Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice","volume":"38","author":"Lett\u00e9ron","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.biochi.2020.08.018_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.211","article-title":"Role of endoplasmic reticulum stress in drug-induced toxicity","volume":"4","author":"Foufelle","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.biochi.2020.08.018_bib83","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2353\/ajpath.2009.090332","article-title":"Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice","volume":"175","author":"Mitchell","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biochi.2020.08.018_bib84","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1111\/j.1742-4658.2011.08357.x","article-title":"Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity: mitochondrial CYP2E1","volume":"278","author":"Knockaert","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.biochi.2020.08.018_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109056","article-title":"Cytochrome P450 2E1 and its roles in disease","volume":"322","author":"Guengerich","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biochi.2020.08.018_bib86","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/ALN.0b013e318266c6df","article-title":"Acquired liver injury in the intensive care unit","volume":"117","author":"Lescot","year":"2012","journal-title":"Anesthesiology"},{"key":"10.1016\/j.biochi.2020.08.018_bib87","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/toxsci\/kfs208","article-title":"Palmitate increases the susceptibility of cells to drug-induced toxicity: an in\u00a0vitro method to identify drugs with potential contraindications in patients with metabolic disease","volume":"129","author":"Luo","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biochi.2020.08.018_bib88","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ajpath.2012.12.033","article-title":"A\u00a0unifying ontology to integrate histological and clinical observations for drug-induced liver injury","volume":"182","author":"Wang","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.biochi.2020.08.018_bib89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/BJ20150195","article-title":"Lopimune-induced mitochondrial toxicity is attenuated by increased uncoupling protein-2 level in treated mouse hepatocytes","volume":"468","author":"Hoss","year":"2015","journal-title":"Biochem. J."},{"key":"10.1016\/j.biochi.2020.08.018_bib90","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4269\/ajtmh.20-0276","article-title":"Case report: hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19","volume":"102","author":"Falc\u00e3o","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.biochi.2020.08.018_bib91","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1038\/sj.onc.1206622","article-title":"Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine","volume":"22","author":"Boya","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.biochi.2020.08.018_bib92","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/jat.1194","article-title":"Cytotoxicity of chloroquine in isolated rat hepatocytes","volume":"27","author":"Jamshidzadeh","year":"2007","journal-title":"J.\u00a0Appl. Toxicol."},{"key":"10.1016\/j.biochi.2020.08.018_bib93","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin-induced liver injury","volume":"13","author":"Martinez","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biochi.2020.08.018_bib94","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/jps.23584","article-title":"An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters","volume":"102","author":"Yang","year":"2013","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.biochi.2020.08.018_bib95","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfx015","article-title":"Antibiotic-induced elevations of plasma bile acids in rats independent of bsep inhibition","author":"Li","year":"2017","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.biochi.2020.08.018_bib96","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11095-019-2582-y","article-title":"Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling","volume":"36","author":"Woodhead","year":"2019","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.biochi.2020.08.018_bib97","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3390\/antibiotics8030110","article-title":"Mitochondrial toxicity of azithromycin results in aerobic glycolysis and DNA damage of human mammary epithelia and fibroblasts","volume":"8","author":"Jiang","year":"2019","journal-title":"Antibiotics"},{"key":"10.1016\/j.biochi.2020.08.018_bib98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40264-020-00954-z","article-title":"Drug-induced liver injury and COVID-19 infection: the rules remain the same","volume":"43","author":"Olry","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.biochi.2020.08.018_bib99","article-title":"Drug-induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors","volume":"28","author":"Leegwater","year":"2020","journal-title":"Clin. Infect. Dis. Jun"},{"key":"10.1016\/j.biochi.2020.08.018_bib100","article-title":"First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19","volume":"17","author":"Muhovi\u0107","year":"2020","journal-title":"Liver Int. May"}],"container-title":["Biochimie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908420302030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300908420302030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:19:46Z","timestamp":1759540786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300908420302030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":100,"alternative-id":["S0300908420302030"],"URL":"https:\/\/doi.org\/10.1016\/j.biochi.2020.08.018","relation":{},"ISSN":["0300-9084"],"issn-type":[{"value":"0300-9084","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?","name":"articletitle","label":"Article Title"},{"value":"Biochimie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biochi.2020.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and Soci\u00e9t\u00e9 Fran\u00e7aise de Biochimie et Biologie Mol\u00e9culaire (SFBBM). All rights reserved.","name":"copyright","label":"Copyright"}]}}